# OnCo record her2 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/her2/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "her2" ;
  schema:name "HER2"@en ;
  schema:description "A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers."@en ;
  schema:url <https://onco.cc/targets/her2/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/HER2/neu>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141736>, <https://www.uniprot.org/uniprotkb/P04626/entry>, <https://www.ncbi.nlm.nih.gov/gene/2064> ;
  schema:citation <https://en.wikipedia.org/wiki/HER2/neu> ;
  onco:tag "adc-target", "driver" ;
  schema:alternateName "ERBB2" ;
  onco:targetClass "surface-antigen" ;
  onco:firstDescribed "1985"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/her2-ish-amplified/>, <https://onco.cc/biomarkers/her2-ihc-3-plus/>, <https://onco.cc/biomarkers/her2-mutation/>, <https://onco.cc/biomarkers/her2-ihc-2-plus/>, <https://onco.cc/biomarkers/her2-ihc-1-plus/>, <https://onco.cc/biomarkers/her2-ihc-0/>, <https://onco.cc/biomarkers/her2-low-ihc/>, <https://onco.cc/biomarkers/her2-ultralow/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:technologies <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/her2-testing-assays/>, <https://onco.cc/drugs/tqb2102/>, <https://onco.cc/drugs/kn026/>, <https://onco.cc/drugs/ibi354/>, <https://onco.cc/drugs/a166/>, <https://onco.cc/drugs/hlx22/>, <https://onco.cc/drugs/glsi-100/>, <https://onco.cc/drugs/hlx11/>, <https://onco.cc/drugs/rph-051/>, <https://onco.cc/drugs/ro7771950/>, <https://onco.cc/drugs/ose2101/>, <https://onco.cc/drugs/gq1005/>, <https://onco.cc/drugs/iah0968/>, <https://onco.cc/drugs/tqb2930/>, <https://onco.cc/drugs/ssgj-705/>, <https://onco.cc/drugs/avzo-021/>, <https://onco.cc/drugs/cinrebafusp-alfa/>, <https://onco.cc/drugs/absk061/>, <https://onco.cc/drugs/ssgj-612/> ;
  onco:companies <https://onco.cc/companies/dualitybio/>, <https://onco.cc/companies/amunix-pharmaceuticals/>, <https://onco.cc/companies/callio-therapeutics/>, <https://onco.cc/companies/cogent-biosciences/>, <https://onco.cc/companies/dantari/>, <https://onco.cc/companies/enliven-therapeutics/>, <https://onco.cc/companies/ibex-medical-analytics/>, <https://onco.cc/companies/iksuda-therapeutics/>, <https://onco.cc/companies/imagene-ai/>, <https://onco.cc/companies/myricx-bio/>, <https://onco.cc/companies/orum-therapeutics/>, <https://onco.cc/companies/precirix/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/bladder-cancer-signalling/>, <https://onco.cc/pathways/breast-cancer-signalling/>, <https://onco.cc/pathways/endometrial-cancer-signalling/>, <https://onco.cc/pathways/gastric-cancer-signalling/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/her2-low/>, <https://onco.cc/terms/gene-amplification/>, <https://onco.cc/terms/her2-testing-in-biliary-cancer/> ;
  onco:trials <https://onco.cc/trials/nct06043817/>, <https://onco.cc/trials/nct07589517/>, <https://onco.cc/trials/nct05532696/>, <https://onco.cc/trials/nct07510802/>, <https://onco.cc/trials/nct05523947/>, <https://onco.cc/trials/nct06369831/>, <https://onco.cc/trials/nct07467863/>, <https://onco.cc/trials/nct06616766/>, <https://onco.cc/trials/nct06439771/>, <https://onco.cc/trials/nct05771584/>, <https://onco.cc/trials/nct07641023/>, <https://onco.cc/trials/nct07462650/>, <https://onco.cc/trials/nct07192432/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-slamon-her2-breast-ovarian-science-1989/>, <https://onco.cc/key-papers/paper-yarden-sliwkowski-erbb-network-nrmcb-2001/>, <https://onco.cc/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/>, <https://onco.cc/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/>, <https://onco.cc/key-papers/paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026/>, <https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/>, <https://onco.cc/key-papers/paper-waddell-whole-genomes-pancreatic-nature-2015/>, <https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/>, <https://onco.cc/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/>, <https://onco.cc/key-papers/paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016/>, <https://onco.cc/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/>, <https://onco.cc/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/>, <https://onco.cc/key-papers/paper-seshagiri-rspo-fusions-colon-nature-2012/>, <https://onco.cc/key-papers/paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024/>, <https://onco.cc/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/>, <https://onco.cc/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/>, <https://onco.cc/key-papers/paper-javle-biliary-ngs-cancer-2016/>, <https://onco.cc/key-papers/paper-hiraoka-her2-status-biliary-hum-pathol-2020/>, <https://onco.cc/key-papers/paper-roa-her2-overexpression-gallbladder-gcr-2014/>, <https://onco.cc/key-papers/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026/>, <https://onco.cc/key-papers/paper-harding-lancet-oncol/>, <https://onco.cc/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/>, <https://onco.cc/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/>, <https://onco.cc/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/>, <https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/>, <https://onco.cc/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/> .